Maxim Group analyst Jason McCarthy maintained a Buy rating on Immutep Limited (Other OTC: IMMP) today and set a price target of $7. The company’s shares opened today at $2.70.
McCarthy said:
“Immutep provided a clinical update for its in-house and partnered LAG-3 programs; Eftilagimod (Efti, IMP321), GSK’781 (formerly IMP731) and LAG525.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 10.8% and a 43.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immutep Limited with a $7 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.06 and a one-year low of $1.25. Currently, Immutep Limited has an average volume of 86.52K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immutep Ltd. is a biotechnology company, which engages in developing immunotherapeutic products for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
